The therapeutic application of PD-1/PD-L1 inhibitors disrupts the binding between PD-1 and PD-L1, thereby restoring T-cell functionality, which effectively targets and destroys tumor cells, enhancing pathological response. The gene discussed is CD274; the disease is neoplasm.